1. Home
  2. ZTO vs BDTX Comparison

ZTO vs BDTX Comparison

Compare ZTO & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZTO

ZTO Express (Cayman) Inc. each representing one ordinary share.

HOLD

Current Price

$20.58

Market Cap

16.3B

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.97

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZTO
BDTX
Founded
2002
2014
Country
China
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.3B
171.9M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
ZTO
BDTX
Price
$20.58
$1.97
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$23.65
$9.67
AVG Volume (30 Days)
1.7M
487.0K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
2.72%
N/A
EPS Growth
N/A
130.71
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.01
N/A
Revenue Next Year
$9.12
N/A
P/E Ratio
$21.83
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.11
$1.60
52 Week High
$26.20
$4.94

Technical Indicators

Market Signals
Indicator
ZTO
BDTX
Relative Strength Index (RSI) 28.57 41.85
Support Level N/A $1.61
Resistance Level $22.84 $2.28
Average True Range (ATR) 0.33 0.10
MACD -0.02 -0.03
Stochastic Oscillator 29.30 3.75

Price Performance

Historical Comparison
ZTO
BDTX

About ZTO ZTO Express (Cayman) Inc. each representing one ordinary share.

ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 20.1% in 2026. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and a major shareholder with 78.7% voting rights as of March 31, 2026. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around a 9.3% interest.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: